- Open Access
© Humana Press Inc 2006
The future of cancer diagnostics will be based on a panel of proteomic biomarkers. They could be used to detect cancer at an early stage, to predict and to direct therapies. Enzymes and related proteins are important biological molecules, which could serve as cancer biomarkers. These biomarkers could be intact or fragments of proteins. The challenge is to be able to find and validate these potential biomarkers as clinical diagnostics. With the advances in proteomic technologies, we are closer than ever to find these “new” enzyme molecules or fragments. The translation of newly discovered biomarkers could provide an opportunity to revolutionize the era of personalized medicine.